<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39371262</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1179-1454</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Journal of experimental pharmacology</Title><ISOAbbreviation>J Exp Pharmacol</ISOAbbreviation></Journal><ArticleTitle>The Efficacy of Oral/Intravenous Corticosteroid Use in COVID-19 Patients: A Systematic Review.</ArticleTitle><Pagination><StartPage>321</StartPage><EndPage>337</EndPage><MedlinePgn>321-337</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/JEP.S484596</ELocationID><Abstract><AbstractText>The COVID-19 pandemic is prompting extensive investigation into potential treatments, including the use of corticosteroids to manage inflammation and mitigate severe disease outcomes. Therefore, this systematic review aimed to evaluate the efficacy of oral/intravenous corticosteroids in the management of COVID-19. A comprehensive search was conducted across major scientific databases such as MEDLINE, Scopus, and Cochrane for relevant studies published from 2019-2024. The inclusion criteria included studies investigating the use of oral/intravenous corticosteroids in COVID-19 patients &gt;18 years with a randomized placebo-controlled trial method. Non-placebo-controlled studies, studies using combined treatments with other drugs, as well as protocol articles, conference proceedings, review articles, and non-English studies were excluded. A narrative synthesis approach was adopted given the significant methodological diversity. The results showed that a total of 12 studies met the inclusion criteria covering the use of three drugs, including dexamethasone (three), hydrocortisone (two), and methylprednisolone (seven). The outcome parameters used for each study were different. Among the total 12 studies, five showed insignificant results for hydrocortisone (two) and methylprednisolone (three), while others reported significant results. This systematic review suggested that oral/intravenous corticosteroids might confer clinical benefits in the management of COVID-19, particularly in reducing mortality and severe disease outcomes. However, further investigation was needed to establish standardized protocols regarding dosage, duration, and safety considerations to optimize efficacy and minimize potential adverse effects.</AbstractText><CopyrightInformation>© 2024 Latarissa et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Latarissa</LastName><ForeName>Irma Rahayu</ForeName><Initials>IR</Initials><Identifier Source="ORCID">0009-0009-6535-6685</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medication Therapy Adherence Clinic (MTAC), Universitas Padjadjaran, Sumedang, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rendrayani</LastName><ForeName>Farida</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-2727-5974</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iftinan</LastName><ForeName>Ghina Nadhifah</ForeName><Initials>GN</Initials><AffiliationInfo><Affiliation>Medication Therapy Adherence Clinic (MTAC), Universitas Padjadjaran, Sumedang, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suhandi</LastName><ForeName>Cecep</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7746-3271</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meiliana</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Prodia Clinical Laboratory, Central Jakarta, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sormin</LastName><ForeName>Ida Paulina</ForeName><Initials>IP</Initials><AffiliationInfo><Affiliation>Faculty of Pharmacy, University of 17 August 1945 Jakarta, Jakarta, Indonesia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Prodia Diacro Laboratories, Jakarta, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barliana</LastName><ForeName>Melisa Intan</ForeName><Initials>MI</Initials><Identifier Source="ORCID">0000-0003-0015-9604</Identifier><AffiliationInfo><Affiliation>Department of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Sumedang, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lestari</LastName><ForeName>Keri</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-2099-1062</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medication Therapy Adherence Clinic (MTAC), Universitas Padjadjaran, Sumedang, Indonesia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Sumedang, Indonesia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>J Exp Pharmacol</MedlineTA><NlmUniqueID>101530345</NlmUniqueID><ISSNLinking>1179-1454</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">corticosteroid</Keyword><Keyword MajorTopicYN="N">efficacy</Keyword><Keyword MajorTopicYN="N">randomized controlled trial</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>5</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39371262</ArticleId><ArticleId IdType="pmc">PMC11453156</ArticleId><ArticleId IdType="doi">10.2147/JEP.S484596</ArticleId><ArticleId IdType="pii">484596</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929–936. doi:10.1056/NEJMOA2001191</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMOA2001191</ArticleId><ArticleId IdType="pmc">PMC7092802</ArticleId><ArticleId IdType="pubmed">32004427</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 cases | WHO COVID-19 dashboard. Available From: https://data.who.int/dashboards/covid19/cases. Accessed September
7, 2024.</Citation></Reference><Reference><Citation>Li G, Hilgenfeld R, Whitley R, De Clercq E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov. 2023;22(6):449–475. doi:10.1038/s41573-023-00672-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-023-00672-y</ArticleId><ArticleId IdType="pmc">PMC10113999</ArticleId><ArticleId IdType="pubmed">37076602</ArticleId></ArticleIdList></Reference><Reference><Citation>Latarissa IR, Barliana MI, Meiliana A, et al. Efficacy of quinine sulfate in patients with mild-to-moderate COVID-19: A randomized controlled trial. Indo Biomed J. 2023;15(6):366–374. doi:10.18585/INABJ.V15I6.2543</Citation><ArticleIdList><ArticleId IdType="doi">10.18585/INABJ.V15I6.2543</ArticleId></ArticleIdList></Reference><Reference><Citation>Latarissa IR, Meiliana A, Sormin IP, et al. The efficacy of herbal medicines on the length of stay and negative conversion time/rate outcomes in patients with COVID-19: a systematic review. Front Pharmacol. 2024;15:1383359. doi:10.3389/FPHAR.2024.1383359</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FPHAR.2024.1383359</ArticleId><ArticleId IdType="pmc">PMC11169809</ArticleId><ArticleId IdType="pubmed">38873430</ArticleId></ArticleIdList></Reference><Reference><Citation>van Paassen J, Vos JS, Hoekstra EM, Neumann KMI, Boot PC, Arbous SM. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Crit Care. 2020;24(1). doi:10.1186/S13054-020-03400-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S13054-020-03400-9</ArticleId><ArticleId IdType="pmc">PMC7735177</ArticleId><ArticleId IdType="pubmed">33317589</ArticleId></ArticleIdList></Reference><Reference><Citation>Villar J, Confalonieri M, Pastores SM, Umberto Meduri G. Rationale for prolonged corticosteroid treatment in the acute respiratory distress syndrome caused by coronavirus disease 2019. Crit Care Explor. 2020;2(4):E0111. doi:10.1097/CCE.0000000000000111</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCE.0000000000000111</ArticleId><ArticleId IdType="pmc">PMC7188431</ArticleId><ArticleId IdType="pubmed">32426753</ArticleId></ArticleIdList></Reference><Reference><Citation>Alijotas-Reig J, Esteve-Valverde E, Belizna C, et al. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: a comprehensive review. Autoimmun Rev. 2020;19(7):102569. doi:10.1016/J.AUTREV.2020.102569</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.AUTREV.2020.102569</ArticleId><ArticleId IdType="pmc">PMC7252146</ArticleId><ArticleId IdType="pubmed">32376394</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang S, Liu T, Hu Y, et al. Efficacy and safety of glucocorticoids in the treatment of severe community-acquired pneumonia: a meta-analysis. Medicine. 2019;98(26). doi:10.1097/MD.0000000000016239</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000016239</ArticleId><ArticleId IdType="pmc">PMC6616855</ArticleId><ArticleId IdType="pubmed">31261585</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattos-Silva P, Felix NS, Silva PL, et al. Pros and cons of corticosteroid therapy for COVID-19 patients. Respir Physiol Neurobiol. 2020;280:103492. doi:10.1016/J.RESP.2020.103492</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.RESP.2020.103492</ArticleId><ArticleId IdType="pmc">PMC7351052</ArticleId><ArticleId IdType="pubmed">32659271</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KH, Yoon S, Jeong GH, et al. Efficacy of corticosteroids in patients with SARS, MERS and COVID-19: a systematic review and meta-analysis. J Clin Med. 2020;9(8):1–17. doi:10.3390/JCM9082392</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/JCM9082392</ArticleId><ArticleId IdType="pmc">PMC7465945</ArticleId><ArticleId IdType="pubmed">32726951</ArticleId></ArticleIdList></Reference><Reference><Citation>Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):757–767. doi:10.1164/RCCM.201706-1172OC/SUPPL_FILE/DISCLOSURES.PDF</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/RCCM.201706-1172OC/SUPPL_FILE/DISCLOSURES.PDF</ArticleId><ArticleId IdType="pubmed">29161116</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473–475. doi:10.1016/S0140-6736(20)30317-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30317-2</ArticleId><ArticleId IdType="pmc">PMC7134694</ArticleId><ArticleId IdType="pubmed">32043983</ArticleId></ArticleIdList></Reference><Reference><Citation>Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):1525–1531. doi:10.1371/JOURNAL.PMED.0030343</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/JOURNAL.PMED.0030343</ArticleId><ArticleId IdType="pmc">PMC1564166</ArticleId><ArticleId IdType="pubmed">16968120</ArticleId></ArticleIdList></Reference><Reference><Citation>Horby P, Lim WS, Emberson J, et al. Effect of dexamethasone in hospitalized patients with covid-19 – preliminary report. medRxiv. 2020;2020. doi:10.1101/2020.06.22.20137273</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.06.22.20137273</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical management of COVID-19. Available from: https://www.who.int/publications/i/item/clinical-management-of-covid-19/. Accessed March
15, 2024.</Citation></Reference><Reference><Citation>Cochrane handbook for systematic reviews of interventions | cochrane training. Available from: https://training.cochrane.org/handbook. Accessed March
18, 2024.</Citation></Reference><Reference><Citation>Tacconelli E. Systematic reviews: CRD’s guidance for undertaking reviews in health care. Lancet Infect Dis. 2010;10(4):226. doi:10.1016/s1473-3099(10)70065-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(10)70065-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021:372. doi:10.1136/BMJ.N71</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/BMJ.N71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramer WM, Rethlefsen ML, Kleijnen J, Franco OH. Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study. Syst Rev. 2017;6(1):1–12. doi:10.1186/S13643-017-0644-Y/TABLES/5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S13643-017-0644-Y/TABLES/5</ArticleId><ArticleId IdType="pmc">PMC5718002</ArticleId><ArticleId IdType="pubmed">29208034</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12. doi:10.1016/0197-2456(95)00134-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(95)00134-4</ArticleId><ArticleId IdType="pubmed">8721797</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamaati H, Hashemian SMR, Farzanegan B, et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: a preliminary report of a randomized clinical trial. Eur J Pharmacol. 2021;897:173947. doi:10.1016/J.EJPHAR.2021.173947</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.EJPHAR.2021.173947</ArticleId><ArticleId IdType="pmc">PMC7885705</ArticleId><ArticleId IdType="pubmed">33607104</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324(13):1307–1316. doi:10.1001/JAMA.2020.17021</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMA.2020.17021</ArticleId><ArticleId IdType="pmc">PMC7489411</ArticleId><ArticleId IdType="pubmed">32876695</ArticleId></ArticleIdList></Reference><Reference><Citation>Horby P, Lim WS, Emberson J, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704. doi:10.1056/NEJMOA2021436</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMOA2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Munch MW, Meyhoff TS, Helleberg M, et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial. Acta Anaesthesiol Scand. 2021;65(10):1421–1430. doi:10.1111/AAS.13941</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/AAS.13941</ArticleId><ArticleId IdType="pmc">PMC8441888</ArticleId><ArticleId IdType="pubmed">34138478</ArticleId></ArticleIdList></Reference><Reference><Citation>Dequin PF, Heming N, Meziani F, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically Ill patients with COVID-19: a randomized clinical trial. JAMA. 2020;324(13):1298–1306. doi:10.1001/JAMA.2020.16761</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMA.2020.16761</ArticleId><ArticleId IdType="pmc">PMC7489432</ArticleId><ArticleId IdType="pubmed">32876689</ArticleId></ArticleIdList></Reference><Reference><Citation>Corral-Gudino L, Bahamonde A, Arnaiz-Revillas F, et al. Methylprednisolone in adults hospitalized with COVID-19 pneumonia: an open-label randomized trial (GLUCOCOVID). Wien Klin Wochenschr. 2021;133(7–8):303–311. doi:10.1007/S00508-020-01805-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00508-020-01805-8</ArticleId><ArticleId IdType="pmc">PMC7854876</ArticleId><ArticleId IdType="pubmed">33534047</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang X, Feng YM, Ni JX, et al. Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomized control trial. Respiration. 2021;100(2):116–126. doi:10.1159/000512063</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000512063</ArticleId><ArticleId IdType="pmc">PMC7900459</ArticleId><ArticleId IdType="pubmed">33486496</ArticleId></ArticleIdList></Reference><Reference><Citation>Edalatifard M, Akhtari M, Salehi M, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. Eur Respir J. 2020;56(6):2002808. doi:10.1183/13993003.02808-2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02808-2020</ArticleId><ArticleId IdType="pmc">PMC7758541</ArticleId><ArticleId IdType="pubmed">32943404</ArticleId></ArticleIdList></Reference><Reference><Citation>Issak ER, Amin MM. Timing of corticosteroids in non-severe non-hospitalized COVID-19 patients: open-label, two-center, randomized controlled study (TICS-COV19 study). Korean J Intern Med. 2023;38(2):207–217. doi:10.3904/KJIM.2022.232</Citation><ArticleIdList><ArticleId IdType="doi">10.3904/KJIM.2022.232</ArticleId><ArticleId IdType="pmc">PMC9993104</ArticleId><ArticleId IdType="pubmed">36646988</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvarani C, Massari M, Costantini M, et al. Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial. Eur Respir J. 2022;60(4):2200025. doi:10.1183/13993003.00025-2022</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00025-2022</ArticleId><ArticleId IdType="pmc">PMC8971731</ArticleId><ArticleId IdType="pubmed">35361632</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeronimo CMP, Farias MEL, Val FFA, et al. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease 2019 (COVID-19; Metcovid): a Randomized, Double-blind, Phase IIb, Placebo-controlled Trial. Clin Infect Dis. 2021;72(9):E373–E381. doi:10.1093/CID/CIAA1177</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/CID/CIAA1177</ArticleId><ArticleId IdType="pmc">PMC7454320</ArticleId><ArticleId IdType="pubmed">32785710</ArticleId></ArticleIdList></Reference><Reference><Citation>Les I, Loureiro-Amigo J, Capdevila F, et al. Methylprednisolone pulses in hospitalized COVID-19 patients without respiratory failure: a randomized controlled trial. Front Med. 2022:9. doi:10.3389/FMED.2022.807981</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FMED.2022.807981</ArticleId><ArticleId IdType="pmc">PMC8919087</ArticleId><ArticleId IdType="pubmed">35295605</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/S0140-6736(20)30211-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30211-7</ArticleId><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi:10.1001/JAMA.2020.1585</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMA.2020.1585</ArticleId><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Emergencias. 2021;33(6):466–467. doi:10.1002/14651858.CD010406.PUB3/MEDIA/CDSR/CD010406/IMAGE_N/NCD010406-CMP-001-03.PNG</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD010406.PUB3/MEDIA/CDSR/CD010406/IMAGE_N/NCD010406-CMP-001-03.PNG</ArticleId><ArticleId IdType="pubmed">34813195</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemieniuk RAC, Meade MO, Alonso-Coello P, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med. 2015;163(7):519–528. doi:10.7326/M15-0715</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M15-0715</ArticleId><ArticleId IdType="pubmed">26258555</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids — new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711–1723. doi:10.1056/NEJMRA050541</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMRA050541</ArticleId><ArticleId IdType="pubmed">16236742</ArticleId></ArticleIdList></Reference><Reference><Citation>Corticosteroids for COVID-19. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1. Accessed March
15, 2024.</Citation></Reference><Reference><Citation>Romanou V, Koukaki E, Chantziara V, et al. Dexamethasone in the treatment of COVID-19: primus inter pares? J Pers Med. 2021;11(6):556. doi:10.3390/JPM11060556</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/JPM11060556</ArticleId><ArticleId IdType="pmc">PMC8232727</ArticleId><ArticleId IdType="pubmed">34203880</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JAC, Murthy S, Jv. D, et al. Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330–1341. doi:10.1001/JAMA.2020.17023</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMA.2020.17023</ArticleId><ArticleId IdType="pmc">PMC7489434</ArticleId><ArticleId IdType="pubmed">32876694</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Saber Batiha G, Al-Gareeb AI, Saad HM, Al-kuraishy HM. COVID-19 and corticosteroids: a narrative review. Inflammopharmacology. 2022;30(4):1189. doi:10.1007/S10787-022-00987-Z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S10787-022-00987-Z</ArticleId><ArticleId IdType="pmc">PMC9106274</ArticleId><ArticleId IdType="pubmed">35562628</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasan SS, Kow CS, Mustafa ZU, Merchant HA. Does methylprednisolone reduce the mortality risk in hospitalized COVID-19 patients? A meta-analysis of randomized control trials. Expert Rev Respir Med. 2021;15(8):1049–1055. doi:10.1080/17476348.2021.1925546</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17476348.2021.1925546</ArticleId><ArticleId IdType="pubmed">33945381</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Wang H, Li S, Liu J, Qiao L. A systematic review and meta-analysis of glucocorticoids treatment in severe COVID-19: methylprednisolone versus dexamethasone. BMC Infect Dis. 2023;23(1). doi:10.1186/S12879-023-08280-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S12879-023-08280-2</ArticleId><ArticleId IdType="pmc">PMC10162003</ArticleId><ArticleId IdType="pubmed">37147596</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebrahimi Chaharom F, Pourafkari L, Ebrahimi Chaharom AA, Nader ND. Effects of corticosteroids on Covid-19 patients: a systematic review and meta-analysis on clinical outcomes. Pulm Pharmacol Ther. 2022;72:102107. doi:10.1016/J.PUPT.2021.102107</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.PUPT.2021.102107</ArticleId><ArticleId IdType="pmc">PMC8684054</ArticleId><ArticleId IdType="pubmed">34933068</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulakurthi YS, Pederson JM, Saravu K, et al. Corticosteroid therapy for COVID-19: a systematic review and meta-analysis of randomized controlled trials. Medicine. 2021;100(20):e25719. doi:10.1097/MD.0000000000025719</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000025719</ArticleId><ArticleId IdType="pmc">PMC8137023</ArticleId><ArticleId IdType="pubmed">34011029</ArticleId></ArticleIdList></Reference><Reference><Citation>Tlayjeh H, Mhish OH, Enani MA, et al. Association of corticosteroids use and outcomes in COVID-19 patients: a systematic review and meta-analysis. J Infect Public Health. 2020;13(11):1652–1663. doi:10.1016/J.JIPH.2020.09.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JIPH.2020.09.008</ArticleId><ArticleId IdType="pmc">PMC7522674</ArticleId><ArticleId IdType="pubmed">33008778</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang JW, Yang L, Luo RG, Xu JF. Corticosteroid administration for viral pneumonia: COVID-19 and beyond. Clin Microbiol Infect. 2020;26(9):1171–1177. doi:10.1016/J.CMI.2020.06.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CMI.2020.06.020</ArticleId><ArticleId IdType="pmc">PMC7320691</ArticleId><ArticleId IdType="pubmed">32603802</ArticleId></ArticleIdList></Reference><Reference><Citation>Isidori AM, Arnaldi G, Boscaro M, et al. COVID-19 infection and glucocorticoids: update from the Italian society of endocrinology expert opinion on steroid replacement in adrenal insufficiency. J Endocrinol Invest. 2020;43(8):1141–1147. doi:10.1007/S40618-020-01266-W</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S40618-020-01266-W</ArticleId><ArticleId IdType="pmc">PMC7182741</ArticleId><ArticleId IdType="pubmed">32335855</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirbhate E, Pandey J, Patel VK, et al. Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention. Pharmacol Rep. 2021;73(6):1539–1550. doi:10.1007/S43440-021-00303-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S43440-021-00303-6</ArticleId><ArticleId IdType="pmc">PMC8236094</ArticleId><ArticleId IdType="pubmed">34176080</ArticleId></ArticleIdList></Reference><Reference><Citation>Montazersaheb S, Hosseiniyan Khatibi SM, Hejazi MS, et al. COVID-19 infection: an overview on cytokine storm and related interventions. Virol J. 2022;19(1). doi:10.1186/S12985-022-01814-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S12985-022-01814-1</ArticleId><ArticleId IdType="pmc">PMC9134144</ArticleId><ArticleId IdType="pubmed">35619180</ArticleId></ArticleIdList></Reference><Reference><Citation>Mcmahon JH, FRACPA U, Anton FCICM, Peleg Y. Remdesivir for the treatment of Covid-19 — preliminary report. N Engl J Med. 2020;383(10):992–994. doi:10.1056/NEJMC2022236</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMC2022236</ArticleId><ArticleId IdType="pubmed">32649075</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh AK, Majumdar S, Singh R, Misra A. Role of corticosteroid in the management of COVID-19: a systemic review and a clinician’s perspective. Diabetes Metab Syndr. 2020;14(5):971. doi:10.1016/J.DSX.2020.06.054</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.DSX.2020.06.054</ArticleId><ArticleId IdType="pmc">PMC7320713</ArticleId><ArticleId IdType="pubmed">32610262</ArticleId></ArticleIdList></Reference><Reference><Citation>Langarizadeh MA, Tavakoli MR, Abiri A, Ghasempour A, Rezaei M, Ameri A. A review on function and side effects of systemic corticosteroids used in high-grade COVID-19 to prevent cytokine storms. EXCLI J. 2021;20:339. doi:10.17179/EXCLI2020-3196</Citation><ArticleIdList><ArticleId IdType="doi">10.17179/EXCLI2020-3196</ArticleId><ArticleId IdType="pmc">PMC7975631</ArticleId><ArticleId IdType="pubmed">33746666</ArticleId></ArticleIdList></Reference><Reference><Citation>Corticosteroids for COVID-19. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1. Accessed September
7, 2024.</Citation></Reference><Reference><Citation>Saal M, Loeffler-Wirth H, Gruenewald T, Doxiadis I, Lehmann C. Genetic Predisposition to SARS-CoV-2 Infection: cytokine Polymorphism and Disease Transmission within Households. Biology. 2023;12(11):1385. doi:10.3390/BIOLOGY12111385/S1</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/BIOLOGY12111385/S1</ArticleId><ArticleId IdType="pmc">PMC10669642</ArticleId><ArticleId IdType="pubmed">37997984</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang JJ, Dong X, Liu GH, Gao YD. Risk and protective factors for COVID-19 morbidity, severity, and mortality. Clin Rev Allergy Immunol. 2023;64(1):90–107. doi:10.1007/S12016-022-08921-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S12016-022-08921-5</ArticleId><ArticleId IdType="pmc">PMC8767775</ArticleId><ArticleId IdType="pubmed">35044620</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Chi J, Lv W, Wang Y. Obesity and diabetes as high‐risk factors for severe coronavirus disease 2019 (Covid‐19). Diabetes Metab Res Rev. 2021;37(2). doi:10.1002/DMRR.3377</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/DMRR.3377</ArticleId><ArticleId IdType="pmc">PMC7361201</ArticleId><ArticleId IdType="pubmed">32588943</ArticleId></ArticleIdList></Reference><Reference><Citation>Landstra CP, de Koning EJP. COVID-19 and diabetes: understanding the interrelationship and risks for a severe course. Front Endocrinol. 2021;12. doi:10.3389/FENDO.2021.649525</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FENDO.2021.649525</ArticleId><ArticleId IdType="pmc">PMC8247904</ArticleId><ArticleId IdType="pubmed">34220706</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyerowitz EA, Sen P, Schoenfeld SR, et al. Immunomodulation as treatment for severe coronavirus disease 2019: a systematic review of current modalities and future directions. Clin Infect Dis. 2021;72(12):E1130–E1143. doi:10.1093/CID/CIAA1759</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/CID/CIAA1759</ArticleId><ArticleId IdType="pmc">PMC7717185</ArticleId><ArticleId IdType="pubmed">33216852</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A, Ahmad Farouk I, Lal SK. COVID-19: a review on the novel coronavirus disease evolution, transmission, detection, control and prevention. Viruses. 2021;13(2):202. doi:10.3390/V13020202</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/V13020202</ArticleId><ArticleId IdType="pmc">PMC7911532</ArticleId><ArticleId IdType="pubmed">33572857</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruciani M, Pati I, Masiello F, Pupella S, De Angelis V. Corticosteroids use for COVID-19: an overview of systematic reviews. Infez Med. 2022;30(4):469. doi:10.53854/LIIM-3004-1</Citation><ArticleIdList><ArticleId IdType="doi">10.53854/LIIM-3004-1</ArticleId><ArticleId IdType="pmc">PMC9714993</ArticleId><ArticleId IdType="pubmed">36482954</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):1–25. doi:10.1186/1710-1492-9-30/TABLES/11</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1710-1492-9-30/TABLES/11</ArticleId><ArticleId IdType="pmc">PMC3765115</ArticleId><ArticleId IdType="pubmed">23947590</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko JJ, Wu C, Mehta N, Wald-Dickler N, Yang W, Qiao R. A comparison of methylprednisolone and dexamethasone in intensive care patients with COVID-19. J Intensive Care Med. 2021;36(6):673–680. doi:10.1177/0885066621994057</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0885066621994057</ArticleId><ArticleId IdType="pubmed">33632000</ArticleId></ArticleIdList></Reference><Reference><Citation>Carta A, Conversano C. Cost utility analysis of remdesivir and dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study. BMC Health Serv Res. 2021;21(1). doi:10.1186/S12913-021-06998-W</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S12913-021-06998-W</ArticleId><ArticleId IdType="pmc">PMC8449700</ArticleId><ArticleId IdType="pubmed">34537034</ArticleId></ArticleIdList></Reference><Reference><Citation>Crothers K, DeFaccio R, Tate J, et al. Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support. Eur Respir J. 2022;60(1):2102532. doi:10.1183/13993003.02532-2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02532-2021</ArticleId><ArticleId IdType="pmc">PMC8841623</ArticleId><ArticleId IdType="pubmed">34824060</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbass H, Abbott A, Abbott A, et al. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2023;401(10387):1499–1507. doi:10.1016/S0140-6736(23)00510-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)00510-X</ArticleId><ArticleId IdType="pmc">PMC10156147</ArticleId><ArticleId IdType="pubmed">37060915</ArticleId></ArticleIdList></Reference><Reference><Citation>Søvik S, Barrat-Due A, Kåsine T, et al. Corticosteroids and superinfections in COVID-19 patients on invasive mechanical ventilation. J Infect. 2022;85(1):57–63. doi:10.1016/J.JINF.2022.05.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JINF.2022.05.015</ArticleId><ArticleId IdType="pmc">PMC9122884</ArticleId><ArticleId IdType="pubmed">35605805</ArticleId></ArticleIdList></Reference><Reference><Citation>Einarsdottir MJ, Kirui BK, Li H, et al. Impact of chronic oral glucocorticoid treatment on mortality in patients with COVID-19: analysis of a population-based cohort. BMJ Open. 2024;14(3):e080640. doi:10.1136/BMJOPEN-2023-080640</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/BMJOPEN-2023-080640</ArticleId><ArticleId IdType="pmc">PMC10946357</ArticleId><ArticleId IdType="pubmed">38490654</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahl A, Johnson S, Chen NW. Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients. Intern Emerg Med. 2021;16(6):1593–1603. doi:10.1007/S11739-021-02655-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S11739-021-02655-6</ArticleId><ArticleId IdType="pmc">PMC7864133</ArticleId><ArticleId IdType="pubmed">33547620</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>